Tripla negatív emlőrák: vizsgálatok itt: Portugália
8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 16.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Where
- Cascais, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 2400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00 - 3. fázisTaking peopleSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Where
- Amadora, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 1530 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00 - 1. fázisNot yet taking people in PortugáliaA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Porto
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 - 1. fázisNot yet taking people in PortugáliaA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Porto
- Életkor
- 18 év and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 - 2/3. fázisFut, nem toborozA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Where
- Coimbra, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00 - 2. fázisTaking peopleStudy to compare the activation of the immune system depending on the chemotherapy scheme used together with PEMBROLIZUM (immunotherapy) in the pre-surgical treatment of triple-negative breast cancer
- Where
- Lisbon, Porto
- Életkor
- 18 év and over
- People
- 20
- Run by
- Champalimaud Clinical Centre
See details and how to join2023-507008-30-00 - 1/2. fázisTaking peopleCircadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
- Where
- Vila Nova de Gaia
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
See details and how to joinNCT06880029 - 2. fázisNot yet taking people in PortugáliaTrial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
- Where
- Lisbon, Porto
- Életkor
- 18 év to 100 év
- People
- 20
- Run by
- Fundacao Champalimaud
See details and how to joinNCT06371807